Starton Holdings plans $40M IPO for cancer drug delivery innovations, but weak IP and limited backing make this a potentially ...
SurvivorNet on MSN
Enabling hope: Lilly’s head of oncology has a hugely ambitious plan to create the next wave of cancer drugs & incredible resources to make it happen
For Jacob Van Naarden, Executive Vice President and President of Lilly Oncology, the mission is clear: bring better cancer ...
A large, multi-institution study led by a Brown University physician-scientist could have important implications for the ...
In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer ...
Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...
The U.S. Food and Drug Administration approved an Investigational New Drug (IND) application using efficacy data solely from ...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...
Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...
Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination ...
Cancer drug resistance is the devastating reason that treatments fail and cancers metastasize, spreading to distant sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback